| Dr Fadi N Joudi, MD | |
|
2626 N Webb Rd, Wichita, KS 67226-8110 | |
| (316) 636-6100 | |
| (316) 636-5813 |
| Full Name | Dr Fadi N Joudi |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 30 Years |
| Location | 2626 N Webb Rd, Wichita, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1427050079 | NPI | - | NPPES |
| 0434399 | Medicaid | IA | |
| 200653860A | Medicaid | KS | |
| 39272 | Other | IA | WELLMARK BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 35511 (Iowa) | Secondary |
| 208800000X | Urology | 04-34329 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pratt Regional Medical Center | Pratt, KS | Hospital |
| Wesley Medical Center | Wichita, KS | Hospital |
| Kansas Spine & Specialty Hospital, Llc | Wichita, KS | Hospital |
| Kingman Community Hospital | Kingman, KS | Hospital |
| Kansas Medical Center Llc | Andover, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Wichita Urology Group Pa | 7214904499 | 23 |
News Archive
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.
Reducing the use of 'low value' interventions that deliver little benefit is vital to cut healthcare costs. In the BJS, investigators have identified 71 low value general surgical procedures, of which five services were of high volume and high cost, 23 were of high cost and low volume, 22 belonged to the low cost and high volume group, and 21 were in the low cost and low volume group.
Allergan plc announced today the U.S. Food and Drug Administration has cleared the XEN Glaucoma Treatment System (consisting of the XEN45 Gel Stent and the XEN Injector) for use in the U.S.
Forest Laboratories announced today its agreement to acquire additional rights to NXL 104, which amends the terms of its prior agreement with Novexel covering the combination of NXL 104 with ceftaroline and adds additional rights to the combination of ceftazidime and NXL 104, through a transaction with AstraZeneca executed immediately following AstraZeneca's announced acquisition of Novexel, S.A.
› Verified 4 days ago
| Entity Name | Wichita Urology Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639157498 PECOS PAC ID: 7214904499 Enrollment ID: O20040916000316 |
News Archive
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.
Reducing the use of 'low value' interventions that deliver little benefit is vital to cut healthcare costs. In the BJS, investigators have identified 71 low value general surgical procedures, of which five services were of high volume and high cost, 23 were of high cost and low volume, 22 belonged to the low cost and high volume group, and 21 were in the low cost and low volume group.
Allergan plc announced today the U.S. Food and Drug Administration has cleared the XEN Glaucoma Treatment System (consisting of the XEN45 Gel Stent and the XEN Injector) for use in the U.S.
Forest Laboratories announced today its agreement to acquire additional rights to NXL 104, which amends the terms of its prior agreement with Novexel covering the combination of NXL 104 with ceftaroline and adds additional rights to the combination of ceftazidime and NXL 104, through a transaction with AstraZeneca executed immediately following AstraZeneca's announced acquisition of Novexel, S.A.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Fadi N Joudi, MD 2626 N Webb Rd, Wichita, KS 67226-8110 Ph: (316) 636-6100 | Dr Fadi N Joudi, MD 2626 N Webb Rd, Wichita, KS 67226-8110 Ph: (316) 636-6100 |
News Archive
AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.
Reducing the use of 'low value' interventions that deliver little benefit is vital to cut healthcare costs. In the BJS, investigators have identified 71 low value general surgical procedures, of which five services were of high volume and high cost, 23 were of high cost and low volume, 22 belonged to the low cost and high volume group, and 21 were in the low cost and low volume group.
Allergan plc announced today the U.S. Food and Drug Administration has cleared the XEN Glaucoma Treatment System (consisting of the XEN45 Gel Stent and the XEN Injector) for use in the U.S.
Forest Laboratories announced today its agreement to acquire additional rights to NXL 104, which amends the terms of its prior agreement with Novexel covering the combination of NXL 104 with ceftaroline and adds additional rights to the combination of ceftazidime and NXL 104, through a transaction with AstraZeneca executed immediately following AstraZeneca's announced acquisition of Novexel, S.A.
› Verified 4 days ago
Dr. Oral E Bass, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 2626 N Webb Rd, Wichita, KS 67226 Phone: 316-636-6100 Fax: 316-636-5813 | |
Dr. Christel Orphee Wambi- Kiesse, M.D. Urology Medicare: Medicare Enrolled Practice Location: 5500 E Kellogg Dr, Wichita, KS 67218 Phone: 316-685-2221 | |
Dr. George F Zakharia, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2626 N Webb Rd, Wichita, KS 67226 Phone: 316-636-6100 Fax: 316-636-5813 | |
William David Mcdonough, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 3311 E Murdock St, Wichita, KS 67208 Phone: 316-689-9234 Fax: 316-689-9909 | |
Rodney G Handsfield, M.D. Urology Medicare: Not Enrolled in Medicare Practice Location: 1130 S Clifton Ave, Wichita, KS 67218 Phone: 316-260-4000 Fax: 316-260-1500 | |
Surendra Kolla, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 3311 E Murdock St, Wichita, KS 67208 Phone: 316-689-9185 | |
Gregory F Byrd, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2626 N Webb Rd, Wichita, KS 67226 Phone: 316-636-6100 Fax: 316-636-5813 |